PHARMACEUTICAL 2024

Royalty Pharma plc
Rank 77 of 309

ROYALTY PHARMA



TOP RATED 2024

RealRate

PHARMACEUTICAL 2024

ROYALTY PHARMA

Royalty Pharma plc
Rank 77 of 309

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 185% points.The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is 307%, being 94% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	1,274,193
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	161,377
Liabilities, Non-Current	6,136,185
Other Assets	15,107,658
Other Compr. Net Income	-565,254
Other Expenses	560,656
Other Liabilities	0
Other Net Income	207,938
Other Revenues	2,354,554
Property and Equipment	0
Research and Development	52,000
Selling, General and Administrative Expense	249,748

Output Variable	Value in 1000 USD
Assets	16,381,851
Liabilities	6,297,562
Expenses	862,404
Revenues	2,354,554
Stockholders Equity	10,084,289
Net Income	1,700,088
Comprehensive Net Income	1,417,461
BaseVar	13,334,782
ECR before LimitedLiability	206%
Economic Capital Ratio	307%